BR0016593A - Métodos para induzir uma resposta imune em um indivìduo contra um patógeno, para tratar um indivìduo suscetìvel a ou que sofre de uma doença associada com um defeito genético e para liberar uma proteìna a um indivìduo, e, composição farmacêutica - Google Patents

Métodos para induzir uma resposta imune em um indivìduo contra um patógeno, para tratar um indivìduo suscetìvel a ou que sofre de uma doença associada com um defeito genético e para liberar uma proteìna a um indivìduo, e, composição farmacêutica

Info

Publication number
BR0016593A
BR0016593A BR0016593A BR0016593A BR0016593A BR 0016593 A BR0016593 A BR 0016593A BR 0016593 A BR0016593 A BR 0016593A BR 0016593 A BR0016593 A BR 0016593A BR 0016593 A BR0016593 A BR 0016593A
Authority
BR
Brazil
Prior art keywords
individual
protein
methods
pathogen
inducing
Prior art date
Application number
BR0016593A
Other languages
English (en)
Inventor
David B Weiner
Jeong-Im Sin
Dong Hui Zhang
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of BR0016593A publication Critical patent/BR0016593A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"MéTODOS PARA INDUZIR UMA RESPOSTA IMUNE EM UM INDIVìDUO CONTRA UM PATóGENO, PARA TRATAR UM INDIVìDUO SUSCETìVEL A OU QUE SOFRE DE UMA DOENçA ASSOCIADA COM UM DEFEITO GENéTICO E PARA LIBERAR UMA PROTEìNA A UM INDIVìDUO, E, COMPOSIçãO FARMACêUTICA". Métodos para induzir respostas imunes em indivíduos contra um patógeno são divulgados. Os métodos para tratar indivíduos suscetíveis a ou que sofrem de uma doença associada com um defeito genético que resulta na não produção ou produção insuficiente de uma proteína ou a produção de uma proteína que não funciona ou que funciona parcialmente são divulgados. Os métodos para liberar uma proteína a um indivíduo são divulgados. Composições farmacêuticas que compreendem cosmídeos são divulgadas.
BR0016593A 1999-12-22 2000-12-22 Métodos para induzir uma resposta imune em um indivìduo contra um patógeno, para tratar um indivìduo suscetìvel a ou que sofre de uma doença associada com um defeito genético e para liberar uma proteìna a um indivìduo, e, composição farmacêutica BR0016593A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17154199P 1999-12-22 1999-12-22
PCT/US2000/035033 WO2001045749A1 (en) 1999-12-22 2000-12-22 Cosmid dna constructs and methods of making and using the same

Publications (1)

Publication Number Publication Date
BR0016593A true BR0016593A (pt) 2002-12-03

Family

ID=22624126

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016593A BR0016593A (pt) 1999-12-22 2000-12-22 Métodos para induzir uma resposta imune em um indivìduo contra um patógeno, para tratar um indivìduo suscetìvel a ou que sofre de uma doença associada com um defeito genético e para liberar uma proteìna a um indivìduo, e, composição farmacêutica

Country Status (13)

Country Link
US (1) US8529884B2 (pt)
EP (1) EP1257298B1 (pt)
JP (1) JP2003518076A (pt)
KR (1) KR100863823B1 (pt)
CN (1) CN1414864A (pt)
AT (1) ATE403443T1 (pt)
AU (1) AU781724B2 (pt)
BR (1) BR0016593A (pt)
CA (1) CA2395435A1 (pt)
DE (1) DE60039786D1 (pt)
IL (1) IL150358A0 (pt)
MX (1) MXPA02006279A (pt)
WO (1) WO2001045749A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7769599B2 (en) 2006-07-31 2010-08-03 Visa U.S.A. Inc. Electronic payment delivery service
WO2017135313A1 (ja) * 2016-02-02 2017-08-10 日東電工株式会社 免疫誘導促進用組成物及びワクチン医薬組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4591505A (en) * 1982-04-14 1986-05-27 New York Blood Center, Inc. Process for inactivating hepatitis B virus
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4746539A (en) * 1983-11-23 1988-05-24 The Ohio State University Research Foundation Purification of cancer-associated protein and preparation of antibody thereto
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4895558A (en) * 1985-07-15 1990-01-23 University Of Queensland Autologous plasma delipidation using a continuous flow system
US4909940A (en) * 1987-12-30 1990-03-20 New York Blood Center, Inc. Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons
US5484396A (en) * 1988-11-17 1996-01-16 Naficy; Sadeque S. Method and device for treatment of HIV infections and AIDS
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0465529T3 (da) 1989-03-21 1998-10-05 Vical Inc Ekspression af exogene polynukleotidsekvenser i et hvirveldyr
WO1993023552A1 (en) 1992-05-21 1993-11-25 Government Of The United States As Represented By Secretary Department Of Health And Human Services Targeting gene expression to living tissue using jet injection
ATE302854T1 (de) * 1993-01-26 2005-09-15 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
PT710126E (pt) * 1993-07-30 2004-09-30 Aruba Internat Pty Ltd Sistema de deslipidacao do plasma
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5736388A (en) * 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US6348353B1 (en) 1995-06-07 2002-02-19 Case Western Reserve University Artificial mammalian chromosome
US5911698A (en) * 1995-12-22 1999-06-15 Aruba International Pty. Ltd. Treatment for cardiovascular and related diseases
US6025155A (en) * 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
WO1997044446A1 (en) 1996-05-24 1997-11-27 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US6277380B1 (en) * 1997-06-04 2001-08-21 The Research Foundation For Microbial Diseases Of Osaka University Measles virus mutant antigen
US6573090B1 (en) * 1998-12-09 2003-06-03 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
CN1409641A (zh) * 1999-11-03 2003-04-09 宝德杰克特疫苗有限公司 基于来源于人及动物病原体基因组构建体的dna疫苗

Also Published As

Publication number Publication date
US20080219953A1 (en) 2008-09-11
DE60039786D1 (de) 2008-09-18
AU781724B2 (en) 2005-06-09
CN1414864A (zh) 2003-04-30
KR20030076217A (ko) 2003-09-26
EP1257298A4 (en) 2004-12-08
MXPA02006279A (es) 2004-02-26
AU2289501A (en) 2001-07-03
US8529884B2 (en) 2013-09-10
ATE403443T1 (de) 2008-08-15
CA2395435A1 (en) 2001-06-28
WO2001045749A1 (en) 2001-06-28
KR100863823B1 (ko) 2008-10-15
EP1257298B1 (en) 2008-08-06
JP2003518076A (ja) 2003-06-03
IL150358A0 (en) 2002-12-01
EP1257298A1 (en) 2002-11-20

Similar Documents

Publication Publication Date Title
BR9814956A (pt) Inibidores de benzotiazol da tirosina cinase de proteìna
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
BRPI0622054B8 (pt) composto e composição farmacêutica
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
BR0316004A (pt) Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina
BR0016126A (pt) Agonistas totais ou parciais de a1 derivados n6 heterocìclicos 5'-tio substituìdos de adenosina
BR0312456A (pt) Anticorpo alterado ou fragmento funcional do mesmo, polinucleotìdeo, sequência de polinucleotìdeo, composição farmacêutica, métodos de tratamento ou profilaxia de derrame e outras doenças/distúrbios neurológicos em um ser humano, de inibição da neurodegeneração e/ou promoção da recuperação funcional e de promoção do desenvolvimento axonial, e, uso de um anticorpo anti-mag
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
BR112012012160A2 (pt) material e métodos para tratar ou prevenir doenças associadas ao her-3
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
BR0316502A (pt) Compostos quìmicos
BRPI0411295A (pt) compostos e seu uso na terapia
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
ATE340515T1 (de) Fraktionierung und behandlung von ölsaatmehl
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BR0114430A (pt) Processos para a indução da morte de células cancerìgenas e para a regressão de tumor
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
ES2096988T3 (es) Organopolisiloxanos que contienen grupos hidrofilos.
BR0016593A (pt) Métodos para induzir uma resposta imune em um indivìduo contra um patógeno, para tratar um indivìduo suscetìvel a ou que sofre de uma doença associada com um defeito genético e para liberar uma proteìna a um indivìduo, e, composição farmacêutica
BR0308515A (pt) Combinação de um antagonista de receptor de aldosterona com ácido nicotìnico ou um derivado de ácido nicotìnico
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
BR9804769A (pt) Processo para tratar ou prevenir infecção por pestivìrus em um hospedeiro mamìfero tendo ou sendo suscetìvel a referida infecção,e , para tratar c~elulas de mamìferos em cultura, e, em mamìferos biológicos
BR0211130A (pt) Plantas transgênicas que expressam proteìnas de ligação da cobalamina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.